Journal Information
Vol. 44. Issue 11.
Pages 629-640 (January 2008)
Share
Share
Download PDF
More article options
Vol. 44. Issue 11.
Pages 629-640 (January 2008)
Recommendations of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)
Full text access
Diagnosis and Treatment of Bronchiectasis
Visits
12897
Montserrat Vendrella,
Corresponding author
mvendrell.girona.ics@gencat.cat

Correspondence: Dra M. Vendrell P.o Canalejas 1, esc. 3, 3.o 1.a 17001 Girona, Spain
, Javier de Graciab, Casilda Olveirac, Miguel Ángel Martínezd, Rosa Giróne, Luis Máizf, Rafael Cantóng, Ramon Collh, Amparo Escribanoi, Amparo Soléj
a Servicio de Neumología, Hospital Josep Trueta, Girona, Spain, CIBER Enfermedades Respiratorias (CibeRes)
b Servicio de Neumología, Hospital Universitari Vall d'Hebron, Barcelona, Spain, CIBER Enfermedades Respiratorias (CibeRes)
c Servicio de Neumología, Hospital Carlos Haya, Málaga, Spain
d Unidad de Neumología, Hospital General, Requena, Valencia Spain
e Servicio de Neumología, Hospital de la Princesa, Madrid, Spain
f Servicio de Neumología, Hospital Ramón y Cajal, Madrid, Spain
g Servicio de Microbiología, Hospital Ramón y Cajal, Madrid, Spain
h Servicio de Rehabilitación, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
i Servicio de Pediatría, Unidad de Neumología Pediátrica, Hospital Clínico Universitario, Universidad de Valencia, Spain
j Unidad de Fibrosis Quística de Adultos y Trasplante Pulmonar, Hospital Universitario La Fe, Valencia, Spain
Ver más
This item has received
Article information

Bronchiectasis is the end result of several different diseases that share principles of management. The clinical course usually involves chronic bronchial infection and inflammation, which are associated with progression. The cause of bronchiectasis should always be investigated, particularly when it can be treated. We recommend evaluating etiology, symptoms, bronchial colonization and infection, respiratory function, inflammation, structural damage, nutritional status, and quality of life in order to assess severity and to monitor clinical course. Care should be supervised by specialized units, at least when there is a history of chronic bronchial infection, recurrent exacerbations, or a cause that is likely to respond to treatment. Improving symptoms and halting progression are the goals of management, which is based on treatment of the underlying cause and of acute or chronic infections and on the drainage of secretions. Complications that arise must also be treated. Antibiotic prescription is guided by monitoring how well infection is being controlled, and this is indicated by the color of sputum and a reduction in the number of exacerbations. We recommend inhaled antibiotics when bronchial infection is chronic and does not respond to oral antibiotics or when these cause side effects, or when the cause is Pseudomonas species or other bacteria resistant to oral antibiotics. Inhaled administration is also advisable to treat initial colonization by Pseudomonas species.

Key words:
Bronchiectasis
Exacerbation
Bronchial colonization
Bronchial infection
Bronchial inflammation

Las bronquiectasias son el resultado final de enfermedades diferentes que tienen puntos de manejo comunes. Suelen cursar con infección e inflamación bronquiales crónicas que se asocian con progresión. Siempre debe investigarse la etiología, en especial de las tributarias de tratamiento. Para valorar la gravedad y hacer el seguimiento, recomendamos evaluar la etiología, la clínica, la colonización-infección bronquial, la función respiratoria, la inflamación, el daño estructural, el estado nutricional y la calidad de vida. Su atención debería realizarse en unidades especializadas, al menos en casos de infección bronquial crónica, agudizaciones repetidas o etiología susceptible de tratamiento. El tratamiento tiene como objetivo mejorar la clínica y detener la progresión, y se basa en el tratamiento de la etiología, de la infección aguda y crónica, en el drenaje de secreciones y en el tratamiento de las complicaciones. La pauta de administración del antibiótico depende del control de la infección, que se comprueba con el color del esputo y la disminución de las agudizaciones. Recomendamos los antibióticos inhalados en la infección bronquial crónica sin respuesta clínica o con efectos secundarios al antibiótico oral, en la causada por Pseudomonas, en la causada por microorganismos resistentes a los antibióticos orales y en la colonización inicial por Pseudomonas.

Palabras clave:
Bronquiectasias
Agudización
Colonización bronquial
Infección bronquial
Inflamación bronquial
Full text is only aviable in PDF
References
[1]
PA Flume, BP O'Sullivan, KA Robinson, CH Goss, PJ Mogayzel, DB Willey-Courand, et al.
Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.
Am J Respir Crit Care Med, 176 (2007), pp. 957-969
[2]
L Máiz, F Baranda, R Coll, C Prados, M Vendrell, A Escribano, et al.
Normativa del diagnóstico y el tratamiento de la afección respiratoria en la fibrosis quística.
Arch Bronconeumol, 37 (2001), pp. 316-324
[3]
J De Gracia, L Máiz, C Prados, M Vendrell, F Baranda, A Escribano, et al.
Antibióticos nebulizados en pacientes con fibrosis quística.
Med Clin (Barc), 117 (2001), pp. 233-237
[4]
R Cantón, N Cobos, J De Gracia, F Baquero, J Honorato, S Gartner, et al.
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Clin Microbiol Infect, 11 (2005), pp. 690-703
[5]
AC Pasteur, SM Helliwell, SJ Houghton, SC Web, JE Foweraker, RA Coulden, et al.
An investigation into causative factors in patients with bronchiectasis.
Am J Respir Crit Care Med, 162 (2000), pp. 1277-1284
[6]
D Weycker, J Edelsberg, G Oster, G Tino.
Prevalence and economic burden of bronchiectasis.
Clin Pulm Med, 12 (2005), pp. 205-209
[7]
M Woodhead, F Blasi, S Ewig, G Huchon, M Leven, A Ortqvist, et al.
Guidelines for the management of adult lower respiratory tract infections.
Eur Respir J, 26 (2005), pp. 1138-1180
[8]
MJ Rosen.
Chronic cough due to bronchiectasis. ACCP Evidence-based clinical practice guidelines.
[9]
HJ Schünemann, R Jaeschke, DJ Cook, WF Bria, AA El-Solh, A Ernst, et al.
An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations.
Am J Respir Crit Care Med, 174 (2006), pp. 605-614
[10]
EY Kang, RR Miller, NL Müller.
Bronchiectasis: comparison of preoperative thin section CT and pathologic findings in resected specimens.
Radiology, 195 (1995), pp. 649-654
[11]
J de Gracia, MJ Rodrigo, F Morell, M Vendrell, M Miravitlles, MJ Cruz, et al.
IgG subclass deficiencies associated with bronchiectasis.
Am J Respir Crit Care Med, 153 (1996), pp. 650-655
[12]
J de Gracia, M Vendrell, A Álvarez, E Pallisa, MJ Rodrigo, D De la Rosa, et al.
Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency.
Int Immunopharmacol, 4 (2004), pp. 745-753
[13]
MJ Rodrigo, M Vendrell, MJ Cruz, M Miravitlles, C Pascual, F Morell, et al.
Utility of the antibody response to a conjugated Haemophilus influenzae type b vaccine for diagnosis of primary humoral immunodeficiency.
Am J Respir Crit Care Med, 162 (2000), pp. 1462-1465
[14]
M Vendrell, J de Gracia, MJ Rodrigo, MJ Cruz, A Álvarez, M García, et al.
Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology.
Chest, 127 (2005), pp. 197-204
[15]
J de Gracia, F Mata, A Álvarez, T Casals, S Gatner, M Vendrell, et al.
Genotype-phenotype correlation for pulmonary function in cystic fibrosis.
Thorax, 60 (2005), pp. 558-563
[16]
PG Noone, MW Leigh, A Sannuti, SL Minnix, JL Carson, M Hazucha, et al.
Primary ciliary dyskinesia. Diagnostic and phenotypic features.
Am J Respir Crit Care Med, 169 (2004), pp. 459-467
[17]
RA Stockley, D Bayley, SL Hill, AT Hill, S Crooks, EJ Campbell.
Assessment of airway neutrophils by sputum colour: correlation with airways inflammation.
Thorax, 56 (2001), pp. 366-372
[18]
J Angrill, C Agustí, R de Celis, X Filella, A Rano, M Elena, et al.
Bronchial inflammation and colonization in patients with clinically stable bronchiectasis.
Am J Respir Crit Care Med, 164 (2001), pp. 1628-1632
[19]
CB Wilson, PW Jones, CJ O'Leary, DM Hansell, RB Dowling, PJ Cole, et al.
Systemic markers of inflammation in stable bronchiectasis.
Eur Respir J, 12 (1998), pp. 820-824
[20]
A Ferrer, V Llorenç, G Codina, J de Gracia.
Nocardiosis y bronquiectasias.
¿Una asociación frecuente? Enferm Infecc Microbiol Clin, 23 (2005), pp. 62-66
[21]
MD Maciá, D Blanquer, B Togores, J Sauleda, JL Pérez, A Oliver.
Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections.
Antimicrob Agents Chemother, 49 (2005), pp. 3382-3386
[22]
M García-Castillo, MI Morosini, A Valverde, F Almaraz, F Baquero, R Cantón, et al.
Differences in biofilm development and antibiotic susceptibility among Streptococcus pneumoniae isolates from cystic fibrosis samples and blood cultures.
J Antimicrob Chemother, 59 (2007), pp. 301-304
[23]
MI Morosini, M García-Castillo, E Loza, M Pérez-Vázquez, F Baquero, R Cantón.
Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.
J Clin Microbiol, 43 (2005), pp. 4480-4485
[24]
MA Martínez-García, JJ Soler-Cataluña, M Perpiñá-Tordera, P Román-Sánchez, JB Soriano.
Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis.
[25]
PL Shah, S Mawdsley, K Nash, P Cullinan, PJ Cole, R Wilson.
Determinants of chronic infection with Staphylococcus aureus in patients with bronchiectasis.
Eur Respir J, 14 (1999), pp. 1340-1344
[26]
DE Griffith, T Aksamit, BA Brown-Elliot, A Catanzaro, C Daley, F Gordin, et al.
Diagnosis, treatment and prevention on nontuberculous mycobacterial diseases.
Am J Respir Crit Care Med, 175 (2007), pp. 367-416
[27]
G Davies, AU Wells, S Doffman, S Watanabe, R Wilson.
The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis.
Eur Respir J, 28 (2006), pp. 974-979
[28]
BW Ramsey, MS Pepe, JM Quan, KL Otto, AB Montgomery, J Williams-Warren, et al.
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis.
N Engl J Med, 340 (1999), pp. 23-30
[29]
G Olveira, A Padilla, C Olveira.
Soporte nutricional en el paciente con patología pulmonar, enfermedad pulmonar obstructiva crónica y fibrosis quística.
Manual de metabolismo y nutrición, pp. 455-470
[30]
MA Martínez-García, M Perpiñá-Tordera, P Román-Sánchez, JJ Soler-Cataluña.
Quality-of-life determinants in patients with clinically stable bronchiectasis.
Chest, 128 (2005), pp. 739-745
[31]
T Marco, O Asensio, M Bosque, J de Gracia, C Serra.
Home intravenous antibiotics for cystic fibrosis.
Cochrane Database Syst Rev, (2000),
[32]
AR Smyth, KH Tan.
Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Cochrane Database Syst Rev, (2006),
[33]
D Bilton, N Henig, B Morrissey, M Gotfried.
Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
Chest, 130 (2006), pp. 1503-1510
[34]
DM Wood, AR Smyth.
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Cochrane Database Syst Rev, (2006),
[35]
DJ Evans, AI Bara, M Greenstone.
Prolonged antibiotics for purulent bronchiectasis in children and adults.
Cochrane Database Syst Rev, (2007),
[36]
AF Barker, L Couch, SB Fiel, MH Gotfried, J Ilowite, KC Meyer, et al.
Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis.
Am J Respir Crit Care Med, 162 (2000), pp. 481-485
[37]
M Vendrell, J de Gracia.
Antibioticoterapia inhalada.
Arch Bronconeumol, 33 (1997), pp. 41-48
[38]
L Saiman, BC Marshall, N Mayer-Hamblett, JL Burns, AL Quittner, DA Cibene, et al.
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA, 290 (2003), pp. 1749-1756
[39]
G Davis, R Wilson.
Prophylactic antibiotic treatment of bronchiectasis with azithromycin.
Thorax, 59 (2004), pp. 540-541
[40]
IM Balfour-Lyn, B Lees, P Hall, G Phillips, M Khan, M Flather, et al.
Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis.
Am J Respir Crit Care Med, 173 (2006), pp. 1356-1362
[41]
MA Martínez-García, M Perpiñá-Tordera, P Román-Sánchez, JJ Soler-Cataluña.
Inhaled steroids improve quality of life in patients with steady-state bronchiectasis.
Resp Med, 100 (2006), pp. 1623-1632
[42]
FD McCool, MJ Rosen.
Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines.
[43]
JM Bradley, FM Moran, JS Elborn.
Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews.
Resp Med, 100 (2006), pp. 191-201
[44]
AJ Crockett, JM Cranston, KM Latimer, JH Alpers.
Mucolytics for bronchiectasis.
Cochrane Database Syst Rev, (2001),
[45]
P Wills, M Greenstone.
Inhaled hyperosmolar agents for bronchiectasis.
Cochrane Database Syst Rev, (2006), pp. f
[46]
A O'Donnell, AF Barker, JS Ilowite, RB Fick.
Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. hDNase study group.
Chest, 113 (1998), pp. 1329-1334
[47]
J Roig, JL Llorente, FJ Ortega, R Orriols.
Manejo de la hemoptisis amenazante.
[48]
JB Orens, M Estenne, S Arcasoy, JV Conte, P Corris, JJ Egan, et al.
International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation.
J Heart Lung Transplant, 25 (2006), pp. 745-755
[49]
K Balkanli, O Genç, M Dakak, S Gürkök, A Gözübüyük, H Caylak, et al.
Surgical management of bronchiectasis: analysis and short-term results in 238 patients.
Eur J Cardiothorac Surg, 24 (2003), pp. 699-702
[50]
K Lavery, B O'Neill, JS Elborn, J Reilly, JM Bradley.
Self-management in bronchiectasis: the patients' perspective.
Eur Respir J, 29 (2007), pp. 541-547
[51]
KM Eastham, AJ Fall, L Mitchell, DA Spencer.
The need to redefine non-cystic fibrosis bronchiectasis in childhood.
Thorax, 59 (2004), pp. 324-327
Copyright © 2008. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?